Prostat kanserinde kallikrein (KLK) gen ailesinin ekspresyon seviyelerinin belirlenmesi

Prostate cancer is one of the deadliest cancer types affecting the male population that results with loss of life. Usually begin to appear after the age of 50, and the incidence increases with advanced age. Diagnosis of prostate cancer at the early stage is important in reducing mortality and morbidity. However, after initial treatment, cancer growth may be slow and recur in 30-90% of male patients with increased prostate cancer risk. The specificity and positive predictive value of prostate specific antigen (PSA), the most widely used biomarker for prostate cancer, is low and the absolute lower limit value for cancer diagnosis has not yet been identified. Biochemical recurrence is defined as an increase in PSA value >0.2 ng/mL, measured twice after radical prostatectomy and nadir PSA value ≥2 ng/mL, after radiotherapy. The Kallikrein (KLK) gene family consist of 15 genes encoding secreted serine proteases that have relevant homologies at both the DNA and amino acid level. Two members of the human kallikrein gene family, prostate specific antigen (PSA) and human kallikrein 2 (hK2), are used clinically as prostate cancer biomarkers. In our study, changes in 15 KLK gene expression levels in 34 recurring 36 non-recurring prostate cancers and 19 normal tissue specimens were investigated. This noninvasive method makes a strong candidate for PCa diagnosis. In conclusion, the difference in expression levels of the KLK gene family in recurrent PCa has been shown for the first time by us in the literature. Easy application of PSA in routine examination and the relationship between prostate cancer and other KLKs have been examined. Our results have shown that KLKs, which are differently expressed in PCa, can be used as recurrence markers. Key words: Prostate Cancer, KLK gene family, gene expression